While CD40-stimulating immunotherapy can enhance anti-tumor responses by activating DCs and increasing T-cells priming, TECs increase Indoleamine 2, 3-dioxygenase 1 (IDO-1), which has an immunosuppressive feedback mechanism that inhibits the response to such immunotherapy [187]. Here, CD40 is linked to neoplasm.